Indications
Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Composition
- Active substance
- siltuximab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Sylvant
- Active substance
- siltuximab
- ATC code
- L04AC11
- Therapeutic area
- Giant Lymph Node Hyperplasia
- Marketing authorisation holder
- Recordati Netherlands B.V.
- Status
- Authorised